Medtronic plc. (MDT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Medtronic plc. (MDT) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How MDT Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $36.36B | 65% | 17.8% | $4.8K | $5.43B | 7.6% |
| FY 2024 | $33.54B | 65.3% | 17.8% | $4.7K | $5.18B | 7.1% |
| FY 2023 | $32.36B | 44% | 15.9% | $3.7K | $5.33B | 9.8% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring MDT)
- ✓Live walkthrough of MDT's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
MDT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MDT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MDT. Explore sector supply chains on /butterfly.
MDT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Medtronic plc. (MDT)?
In FY 2025 (10-K), MDT converted $36.4B of revenue into a 65% gross margin, 17.8% operating margin, and $5.4B in free cash flow (14.9% FCF margin).